Oncology PracticeASCO 2021: Breast cancer sessions not to missJune 4, 2021Breast CancerMetastatic Breast CancerASCO Breast Cancer
Oncology Practice'Exciting': Olaparib benefit also in early BRCA+ breast cancer June 4, 2021Breast CancerASCO Breast Cancer
Oncology PracticeIL-6 levels predict distant breast cancer recurrenceJune 4, 2021Metastatic Breast CancerBreast CancerASCO Breast Cancer
Key Studies in Metastatic Breast Cancer From ASCO 2020June 22, 2020ASCO Breast CancerBreast CancerMetastatic Breast Cancer
Oncology PracticeGermline testing in advanced cancer can lead to targeted treatmentJune 3, 2020Mixed TopicsBreast CancerCNS/Brain CancerGastroenterologyGenitourinary CancerGynecologic CancerHead & Neck/Thyroid Cancers
Oncology PracticeTreating primary tumor doesn’t improve OS in stage IV breast cancerJune 1, 2020Breast CancerASCO Breast CancerMetastatic Breast Cancer
Oncology PracticePyrotinib bests lapatinib in HER2+ metastatic breast cancerMay 31, 2020Breast CancerMetastatic Breast CancerASCO Breast Cancer
Oncology PracticeExpanding the role of PARP inhibitors in breast cancerMay 31, 2020Breast CancerASCO Breast CancerMetastatic Breast Cancer
Oncology PracticeALTERNATE trial: No fulvestrant benefit in locally advanced ER+ HER2– breast cancerMay 31, 2020Breast CancerASCO Breast Cancer
Oncology PracticeTucatinib improves PFS, OS in HER2+ breast cancer with brain metastasesMay 30, 2020Breast CancerASCO Breast CancerMetastatic Breast Cancer
Oncology PracticeTRAIN-2: Anthracyclines added toxicity, with no increased efficacy, in HER2+ breast cancerMay 30, 2020Breast CancerASCO Breast Cancer
Oncology PracticeCapecitabine maintenance improved DFS, not OS, in TNBC patientsMay 30, 2020Breast CancerASCO Breast Cancer
Oncology PracticePPI added to chemo improves breast tumor response rateMay 30, 2020Breast CancerASCO Breast Cancer
Oncology PracticePembrolizumab plus chemo shows benefits for PD-L1–rich triple-negative breast cancerMay 29, 2020Breast CancerASCO Breast CancerMetastatic Breast Cancer
